Efficacy of prostaglandin E1 as adjuvant therapy for mild to moderate acute pancreatitis

Ji Bo; Chen LiYu; Liu YaHui

doi:10.3969/j.issn.1001-5256.2016.01.023

Volume 32 Issue 1

Jan. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(1): 123-126

PDF( 1485 KB)

Efficacy of prostaglandin E1 as adjuvant therapy for mild to moderate acute pancreatitis

DOI: 10.3969/j.issn.1001-5256.2016.01.023

Second Department of Hepatobiliary and Pancreatic Surgery,The First Hospital of Jilin University

Research funding:

Received Date: 2015-07-01
Published Date: 2016-01-20

Abstract

Abstract

Objective To observe the clinical effect and efficacy of prostaglandin E1( PGE1),the drug for microcirculation improvement,in the treatment of acute pancreatitis( AP). Methods A total of 80 patients with mild- to- moderate AP who were hospitalized and treated in Second Department of Hepatobiliary and Pancreatic Surgery of the First Hospital of Jilin University from May 2014 to January 2015 were enrolled and randomized into two groups. Forty- four patients in control group received the conventional comprehensive therapy for AP,and36 patients in experiment group received PGE1 in addition to the conventional therapy. The time to disappearance of abdominal symptoms and the time for serum and urine levels of amylase and serum levels of lipase,C- reactive protein( CRP),and procalcitonin( PCT) to return to normal were compared between the two groups. The independent- samples t- test was applied for comparison of continuous data between the two groups,and the chi- square test or Fisher's exact test was applied for comparison of categorical data between the two groups.Results The two groups had significant differences in the time for serum levels of amylase and CRP and percentage of neutrophils to return to normal and hospital costs( P = 0. 041,0. 030,0. 012,and 0. 026,respectively). PGE1 quickly relieved abdominal pain and distention,reduced the serum level of amylase,shortened the length of hospital stay,and reduced hospital costs. Conclusion PGE1 has good clinical effect and safety in the treatment of AP,and can be applied as an adjuvant drug in the comprehensive therapy for AP.
- pancreatitis,
- prostaglandins E,
- therapy

FullText(HTML)

References(15)

References

[1]Pancreas Study Group,Chinese Society of Gastroenteroloy,Chinese Medical Association,Editorial Board of Chinese Journal of Pancreatolog,Editorial Board of Chinese Journal of Digestion.Chinese guidelines for the management of acute pancreatitis(Shanghai,2013)[J].J Clin Hepatol,2013,29(9):656-660.(in Chinese)中华医学会消化病学分会胰腺疾病学组,《中华胰腺病杂志》编辑委员会,《中华消化杂志》编辑委员会.中国急性胰腺炎诊治指南(2013年,上海)[J].临床肝胆病杂志,2013,29(9):656-660.

[2] Group of Pancreatic Surgery,Chinese Society of Surgery,Chinese Medical Association.Guidelines for the management of acute pancreatitis(2014)[J].J Clin Hepatol,2015,31(1):17-20.(in Chinese)中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南(2014版)[J].临床肝胆病杂志,2015,31(1):17-20.

[3]LIU DY,LEI LM,LIAO ZH,et al.Traditional Chinese medicine in treatment of acute pancreatitis[J].J Changchun Univ Tradit Chin Med,2015,31(4):877-880.(in Chinese)刘冬一,雷力民,廖昭海,等.中医药治疗急性胰腺炎研究进展[J].长春中医药大学学报,2015,31(4):877-880.

[4]JIN C,NI QX,ZHANG QH,et al.The relationship between pancreatic ischemia and cytokines in rats with acute pancreatitis[J].Chin J Gen Surg,2001,16(11):662-664.(in Chinese)金忱,倪泉兴,张群华,等.急性胰腺炎时胰腺缺血与细胞因子相关性的实验研究[J].中华普通外科杂志,2001,16(11):662-664.

[5]ZHANG LF,LI L,LI JC.Application of ameliorating microcirculation to treatment of severe pancreatitis[J].Chin J Pract Intern Med,2002,22(3):163-164.(in Chinese)张连峰,李丽,李继昌.改善微循环在重症胰腺炎治疗中的应用[J].中国实用内科杂志,2002,22(3):163-164.

[6]YCEL K,ALHAN E,KCKTL U,et al.The effects of prostaglandin E1 on the microperfusion of the pancreas during acute necrotizingpancreatitis in rats[J].Hepatogastroenterology,2002,49(44):544-548.

[7]BUSCAIL L,BUSSENOT I,BOUISSON M,et al.Protective effect of misoprostol,a synthetic prostaglandin E1 analog,on ceruleininduced acutepancreatitis in rats[J].Pancreas,1990,5(2):171-176.

[8]CROCKET KV,BRACKETT K,CROCKET A,et al.Prostaglandin E1 treatment in experimental acute pancreatitis in the rat[J].Eur Surg Res,1984,16(5):265-273.

[9]GUO XZ,WU CY.Pay attention to the relationship between etiology and diagnosis of acute pancreatitis[J].Chin J Pract Intern,2014,34(9):836-838.(in Chinese)郭晓钟,吴春燕.重视急性胰腺炎的病因诊断[J].中国实用内科杂志,2014,34(9):836-838.

[10]YU W,WU W,ZHANG SH,et al.Progression of pathogenetic research of acute pancreatitis[J].Chin J Bases Clin General Surg,2006,13(6):733-736.(in Chinese)余文,吴伟,张少辉,等.急性胰腺炎发病机理的研究进展[J].中国普外基础与临床杂志,2006,13(6):733-736.

[11]YANG XF,YANG ZY,ZHOU F,et al.Influence of prostaglandin E1 on cytokines and pancreatic pathology in rats with severe acute pancreatitis[J].Chin J Exp Surg,2006,23(1):112.(in Chinese)杨雪菲,杨智勇,周峰,等.前列腺素E1对大鼠重症急性胰腺炎细胞因子及胰腺病理的影响[J].中华实验外科杂志,2006,23(1):112.

[12] XIE ML.Clinical efficacy of prostaglandin E1 in treatment of acute pancreatitis[J].Med Inf,2013,26(2):154.(in Chinese)谢梦玲.前列腺素E1治疗急性胰腺炎的临床疗效分析[J].医学信息,2013,26(2):154.

[13]WANG LY.Clinical efficacy of prostaglandin E1 combined with Qingyi decoction in treatment of severe acute pancreatitis[J].China Prac Med,2013,8(23):146-147.(in Chinese)王丽娅.前列腺素E1联合清胰汤治疗重症急性胰腺炎的临床观察[J].中国实用医药,2013,8(23):146-147.

[14]CHEN WJ,LIN SB.Effect of somatostatin combined wiith prostaglandin E1 on severe acute pancreatitis[J].Pract Pharm Clin Remed,2013,16(8):741-743.(in Chinese)陈文炯,林少斌.生长抑素联合前列腺素E1治疗重症急性胰腺炎的疗效观察[J].实用药物与临床,2013,16(8):741-743.

[15]ZHAI XG,ZHANG ZH,ZHOU G,et al.Preliminary clinical study of somatostatin combined with prostaglandin E 1 in patients with severe acute pancreatits[J].Chongqing Med,2014,43(1):77-79.(in Chinese)瞿星光,张朝晖,周刚,等.生长抑素与前列腺素E1联合应用治疗重症急性胰腺炎初步临床研究[J].重庆医学,2014,43(1):77-79.

Relative Articles

[1]	Wenhui WANG, Xuhua DUAN, Hao LI, Shuguang JU, Manzhou WANG, Jianzhuang REN, Xinwei HAN. A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2125-2129. doi: 10.3969/j.issn.1001-5256.2021.09.024
[2]	Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027
[3]	Ha FuShuang, Han Tao, Liang Ning, Nie XinHua, Zhu ZhengYan. Effect of recombinant human granulocyte colony-stimulating factor on rats with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1565-1569. doi: 10.3969/j.issn.1001-5256.2019.07.028
[4]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[5]	Zhang YongChao, Bi YanZhen, Fang Xiao, Wang QuanYi, Wang QuanQuan, Tang HuiXin, Kong LingBin, Chen Yu, Duan ZhongPing, Shu ZhenFeng, Hong Feng. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
[6]	Wang Hao, He Cheng, Chen Hao, Ou YangZhongMin, Liu ZhiQiang. Value of Gd-EOB-DTPA-enhanced MRI in the assessment of liver function in dogs with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1576-1581. doi: 10.3969/j.issn.1001-5256.2019.07.030
[7]	Zhou QiFeng, Zhang LingQiang, Liao MengJiao, Pang MingQuan, Li MengXuan, Ren Li, Fan HaiNing. Establishment of a subcutaneous xenograft tumor model of alveolar echinococcosis in nude mice[J]. Journal of Clinical Hepatology, 2018, 34(3): 588-590. doi: 10.3969/j.issn.1001-5256.2018.03.028
[8]	Ji JunSong, Chen Ting, Wang Hui, Wang ChenYi, Zhu XinYing, Yin Hao, Fu ZhiRen. Effect of arsenic trioxide chemotherapy on survival time in liver cancer patients undergoing liver transplantation[J]. Journal of Clinical Hepatology, 2017, 33(9): 1745-1748. doi: 10.3969/j.issn.1001-5256.2017.09.023
[9]	Li Dong, Lu ZhongHua, Gan JianHe. Establishment of a rat model of early-stage liver failure and Th17/Treg imbalance[J]. Journal of Clinical Hepatology, 2016, 32(5): 928-932. doi: 10.3969/j.issn.1001-5256.2016.05.025
[10]	Chen Jing, Liu XiaoYan, Yang HaoZhen, Huang Kun, Hu JinHua, Xin ShaoJie. Study on p-p38 expression and its significance in liver tissues of mice with acute liver failure and patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 556-559. doi: 10.3969/j.issn.1001-5256.2015.04.019
[11]	Pang GuoJin, Chen ShuangJun, Zhao WeiHua, Liu TianHui, Wang Ping, You Hong, Cong Min. Dynamic change of hepcidin in liver fibrosis induced by CCl4 among mice[J]. Journal of Clinical Hepatology, 2015, 31(3): 418-423. doi: 10.3969/j.issn.1001-5256.2015.03.025
[12]	Gao ChengGuang, Chen RiXia. Clinical research on treatment of advanced primary liver cancer with combination of thymosin α1 and arsenic trioxide[J]. Journal of Clinical Hepatology, 2015, 31(4): 564-568. doi: 10.3969/j.issn.1001-5256.2015.04.021
[13]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
[14]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[15]	Jiang Han, Wang XueFeng, Wang ZiHao, Xu Bin, Shi WeiBin. The establishment of rabbit VX2 hepatic tumor model and the application of nano-scale microbubble contrast agent in the diagnosis of this model[J]. Journal of Clinical Hepatology, 2011, 27(7): 746-748.
[16]	Sun LinLin, Shi Jun, Hao JingHua, Ren WanHua, Yan ChunYing, Zhang Jie, Lin XiaoYan, Cui Bin. Effect of high-fat diet on establishment of a rat non-alcoholic steatohepatitis/liver fibrosis model[J]. Journal of Clinical Hepatology, 2011, 27(3): 254-257+272.
[17]	Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.
[18]	Song Yu, Yu Zheng, Fan YanHua, Yao ShuKun, Wang TaiLing. A rat model of hepatic veno-occlusive disease induced by the Gynura root water decoction[J]. Journal of Clinical Hepatology, 2011, 27(8): 860-864.
[19]	Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.

Supplements(0)

Cited By

Cited by

Periodical cited type(10)

1.	杨晓曼. γ-谷氨酰转移酶/血小板在乙肝肝硬化失代偿期患者中的表达及临床意义. 河南医学研究. 2024(08): 1407-1410 .
2.	刘爱华，符建，陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究. 实用肝脏病杂志. 2023(05): 634-637 .
3.	肖少伟，杜亚哲. γ-谷氨酰转移酶/胆碱酯酶比值与γ-谷氨酰转移酶/血小板比值对慢性乙型肝炎患者肝纤维化程度的预测效能. 实用医技杂志. 2023(11): 812-815 .
4.	张玉婷，施欢，李虤，沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
5.	桑阿利. APRI、Fib-4和Fibroscan联合诊断慢性乙型肝炎肝纤维化程度的价值. 甘肃医药. 2022(10): 896-898 .
6.	王晔恺，于倩，姚燕珍，罗雯斌，洪开听，鲍舟君. 对数几率回归模型构建联合预测因子对慢性乙型肝炎患者早期肝硬化诊断的临床应用. 中国卫生检验杂志. 2021(01): 90-93+97 .
7.	陈兴，梁小桃. 肝瞬时弹性成像与天冬氨酸转氨酶/血小板指数在慢性乙型肝炎合并脂肪肝患者肝纤维化诊断中的应用价值. 中国当代医药. 2021(11): 60-62 .
8.	黄腊平，陈焰. 基于Fibroscan技术的柴胡疏肝散对非酒精性脂肪肝患者临床疗效分析. 清远职业技术学院学报. 2020(02): 35-38 .
9.	栗红江，何久胜，胡素玲，何福亮，田彦卿，刘震霞. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能. 临床军医杂志. 2020(09): 1090-1091+1094 .
10.	熊静，林登娜，翁伟镇，陈俊峰，曹会娟，张绍全，张静，高隽，林炳亮. FIB-4联合血清PCⅢ、ⅣC评估乙型肝炎病毒相关肝纤维化. 国际病毒学杂志. 2020(05): 403-406 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2257) PDF downloads(409)

Efficacy of prostaglandin E1 as adjuvant therapy for mild to moderate acute pancreatitis

DOI: 10.3969/j.issn.1001-5256.2016.01.023